Effect of patient-specific factors on weekly warfarin dose.

abstract：OBJECTIVE:The outcome of decompressive craniectomy (DC) for severe traumatic brain injury (sTBI) patients with fixed dilated pupils (FDPs) is not clear. The objective of this study was to validate the outcome of DC in sTBI patients with FDPs. PATIENTS:We retrospectively collected data from 207 sTBI patients with FDPs ...

journal_title：Therapeutics and clinical risk management

authors： Mao X,Miao G,Hao S,Tao X,Hou Z,Li H,Tian R,Zhang H,Lu T,Ma J,Zhang X,Cheng H,Liu B

更新日期：2015-10-22 00:00:00

abstract：:The topoisomerase I inhibitor topotecan is the only single-agent therapy approved for the treatment of recurrent small cell lung cancer (SCLC). Many patients with recurrent SCLC may be predisposed to treatment-related adverse events because of the presence of comorbidities such as advanced age, renal impairment, or ex...

journal_title：Therapeutics and clinical risk management

authors： Garst J

更新日期：2007-12-01 00:00:00

abstract：:Heart failure (HF) is a major public health priority due to its epidemiological transition and the world's aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid and autonomic imbalance, and ventricular dilat...

journal_title：Therapeutics and clinical risk management

authors： Bonsu KO,Owusu IK,Buabeng KO,Reidpath DD,Kadirvelu A

更新日期：2016-06-03 00:00:00

abstract：:Behçet's disease is an autoinflammatory vasculitis of unknown origin characterized by recurrent oral and genital ulcers, uveitis, arthritis and skin lesions. Additionally, involvement of the gastrointestinal tract, central nervous system and large vessels may occur. The disease is prevalent in countries along the anci...

journal_title：Therapeutics and clinical risk management

authors： van Daele PL,Kappen JH,van Hagen PM,van Laar JA

更新日期：2009-04-01 00:00:00

abstract：:Over recent decades, basic research has yielded a large volume of data on many potentially clinically relevant genetic determinants of drug efficacy and toxicity. Until recently, most examples involved genes encoding drug-metabolizing enzymes, particularly the cytochromes P450. More recently, rapid advances in genomic...

journal_title：Therapeutics and clinical risk management

authors： McKinnon RA,Ward MB,Sorich MJ

更新日期：2007-10-01 00:00:00

abstract：BACKGROUND:Internationally, there is a remarkable achievement in the areas of drug discovery, drug design, and clinical trials. New and efficient drug formulation techniques are widely available which have led to success in treatment of several diseases. Despite these achievements, large number of patients continue to ...

journal_title：Therapeutics and clinical risk management

authors： Abubakar AR,Ismail S,Rahman NI,Haque M

更新日期：2015-06-30 00:00:00

abstract：:East Asians are prone to higher systemic exposure and increased risk of bleeding compared to other races after administration of antiplatelet agent(s). The aim of this systematic review was to compare and evaluate the appropriateness of a lower dose versus standard dose of ticagrelor in East Asians. A systematic searc...

journal_title：Therapeutics and clinical risk management

authors： Lee YJ,Kim H,Choi J,Lee BH,Lee SY

更新日期：2018-01-08 00:00:00

abstract：:The purpose of this review was to test contraceptive efficacy, cycle control, tolerability, and acceptability as found in the non-comparative studies with NuvaRing((R)) by those found in the randomized trials comparing NuvaRing and combined oral contraceptives (COCs). All large non-comparative studies and all relevant...

journal_title：Therapeutics and clinical risk management

authors： Roumen FJ

更新日期：2008-04-01 00:00:00

abstract：:Parkinson's disease (PD) is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopamine receptor agonist...

journal_title：Therapeutics and clinical risk management

authors： Lecht S,Haroutiunian S,Hoffman A,Lazarovici P

更新日期：2007-06-01 00:00:00

abstract：:Glucocorticoids are commonly used in various fields within medicine. One of their most common and clinically significant side effects is glucocorticoid-induced osteoporosis (GIOP). GIOP is a disease leading to progressive decreases in bone mineral density, decreased bone strength, and increased risk of skeletal fractu...

journal_title：Therapeutics and clinical risk management

authors： Lau AN,Adachi JD

更新日期：2010-10-21 00:00:00

abstract：INTRODUCTION:Renal cell carcinoma (RCC) represents 2%-3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) in...

journal_title：Therapeutics and clinical risk management

authors： Leonetti A,Leonardi F,Bersanelli M,Buti S

更新日期：2017-06-30 00:00:00

abstract：Purpose:To analyze the treatment patterns of psoriatic arthritis (PSA) or ankylosing spondylitis (AS) patients under biological therapies and to evaluate in this population the health-care resource consumption and related costs. Patients and Methods:A retrospective analysis was performed on administrative databases of...

journal_title：Therapeutics and clinical risk management

authors： Perrone V,Giacomini E,Sangiorgi D,Andretta M,Menti AM,Naclerio M,Ritrovato D,Degli Esposti L

更新日期：2020-06-09 00:00:00

abstract：:Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the...

journal_title：Therapeutics and clinical risk management

authors： Proietti M,Boriani G

更新日期：2018-08-22 00:00:00

abstract：:Chordomas are rare, locally aggressive skull base neoplasms known for local recurrence and not-infrequent treatment failure. Current evidence supports the role of maximal safe surgical resection. In addition to open skull-base approaches, the endoscopic endonasal approach to clival chordomas has been reported with fav...

journal_title：Therapeutics and clinical risk management

authors： Di Maio S,Yip S,Al Zhrani GA,Alotaibi FE,Al Turki A,Kong E,Rostomily RC

更新日期：2015-05-26 00:00:00

abstract：:The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiol...

journal_title：Therapeutics and clinical risk management

authors： Elalouf O,Elkayam O

更新日期：2015-11-19 00:00:00

abstract：:Some specific features of the 24 h blood pressure (BP) pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal BP mean (the diurnal/nocturnal ratio, an index ...

journal_title：Therapeutics and clinical risk management

authors： Hermida RC,Ayala DE,Calvo C

更新日期：2007-03-01 00:00:00

abstract：Introduction:Preservation of endodontically treated teeth (ETT) depends upon several patient-related and operator-related factors. The objectives of this study were to assess the effects of different types of coronal restoration and delayed placement on ETT survival. Methods:Data on dates of root canal treatment (RCT)...

journal_title：Therapeutics and clinical risk management

authors： Sadaf D

更新日期：2020-02-21 00:00:00

abstract：OBJECTIVES:The significance of early ischemic changes (EIC) on computed tomography (CT) within 3 hours after stroke onset remains controversial. The semi-quantitative Alberta Stroke Program Early CT Score (ASPECTS) is found to have prognostic value in early stroke. This study assesses factors associated with the presen...

journal_title：Therapeutics and clinical risk management

authors： Thomassen L,Waje-Andreassen U,Naess H

更新日期：2008-08-01 00:00:00

abstract：:Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the...

journal_title：Therapeutics and clinical risk management

authors： Jain MD,Bachmeier CA,Phuoc VH,Chavez JC

更新日期：2018-05-31 00:00:00

abstract：:Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently...

journal_title：Therapeutics and clinical risk management

authors： Papanagnou P,Baltopoulos P,Tsironi M

更新日期：2015-05-18 00:00:00

abstract：OBJECTIVE:The aim of this study was to compare the knowledge, attitude and barriers of pharmacy technicians and pharmacists toward pharmacovigilance, adverse drug reactions (ADRs) and ADR reporting in community pharmacies in Yemen. METHODS:This cross-sectional survey was conducted among community pharmacists and pharm...

journal_title：Therapeutics and clinical risk management

authors： Al-Worafi YM,Kassab YW,Alseragi WM,Almutairi MS,Ahmed A,Ming LC,Alkhoshaiban AS,Hadi MA

更新日期：2017-09-07 00:00:00

abstract：Purpose:Pharmacological errors are among the most common in the healthcare system. This study aimed to determine the level of safety of the pharmacotherapy process at the stage performed by nurses and midwives by indicating the key risk factors affecting patients' safety. Methods:A group of 1276 nurses and 136 midwive...

journal_title：Therapeutics and clinical risk management

authors： Witczak I,Uchmanowicz I,Tartaglia R,Rypicz Ł

更新日期：2020-11-04 00:00:00

abstract：Introduction:Severe hand, foot, and mouth disease (HFMD) may lead to serious complications, which cause child mortality during outbreaks. The aim of this study was to determine whether neutrophil-to-lymphocyte ratio (NLR) can predict death risk in severe HFMD. Methods:Medical records for 664 severe HFMD patients were ...

journal_title：Therapeutics and clinical risk management

authors： Li Y,Wang M,Wang W,Feng D,Deng H,Zhang Y,Dang S,Zhai S

更新日期：2020-10-23 00:00:00

abstract：BACKGROUND:Adverse drug reactions are important determinants of inpatient and outpatient morbidity. Thiocolchicoside is a semisynthetic derivate of naturally occurring colchicoside, which is largely used in humans as a centrally acting muscle relaxant. Epileptic seizures after thiocolchicoside intake have been reported...

journal_title：Therapeutics and clinical risk management

authors： Giavina-Bianchi P,Giavina-Bianchi M,Tanno LK,Ensina LF,Motta AA,Kalil J

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:To report two cases of chronic postoperative cystoid macular edema, resistant to topical therapy, treated with consecutive intravitreal injections of ketorolac tromethamine. METHODS:Four daily intravitreal injections of 500 μg/0.05 mL of ketorolac were given to each patient. Complete clinical examination and O...

journal_title：Therapeutics and clinical risk management

authors： Tsilimbaris MK,Tsika C,Kymionis GD

更新日期：2016-02-12 00:00:00

abstract：:The Clinical Assessment Program and Teflaro(®) Utilization Registry (CAPTURE) is a multicenter study evaluating the clinical use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. Data were collected between August 2011 and Februa...

journal_title：Therapeutics and clinical risk management

authors： Maggiore C,Vazquez JA,Guervil DJ,Ramani A,Jandourek A,Cole P,Friedland HD

更新日期：2015-04-02 00:00:00

abstract：OBJECTIVE:International travelers from non-endemic areas are at high risk of contracting malaria due to their lack of immunity. Prevention is therefore of outmost importance and is achieved through effective and safe chemoprophylaxis, which reduces the risk of fatal disease. Among the various antimalarial drugs availab...

journal_title：Therapeutics and clinical risk management

authors： Nicosia V,Colombo G,Consentino M,Di Matteo S,Mika F,De Sanctis S,Ratti S,Vinci M

更新日期：2008-10-01 00:00:00

abstract：:Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and...

journal_title：Therapeutics and clinical risk management

authors： Gennari L,Merlotti D,De Paola V,Martini G,Nuti R

更新日期：2008-12-01 00:00:00

abstract：:Daptomycin is a novel bactericidal antibiotic with excellent activity against gram-positive organisms. It is a large cyclic lipopeptide with a unique mechanism of action. Daptomycin is given once a day and is renally cleared, requiring dose adjustment in patients with impaired renal function. Unfortunately, there have...

journal_title：Therapeutics and clinical risk management

authors： Shoemaker DM,Simou J,Roland WE

更新日期：2006-06-01 00:00:00

abstract：:Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage. AKs have historically been characterized as being "precancerous"; however, now it is considered by many author...

journal_title：Therapeutics and clinical risk management

authors： Skroza N,Bernardini N,Proietti I,Potenza C

更新日期：2018-10-04 00:00:00